Karyopharm Therapeutics
Kristin Abate is an experienced finance professional currently serving as Vice President, Accounting & Corporate Controller at Karyopharm Therapeutics Inc. since July 2019, where roles have included Executive Director and Senior Director of Accounting and Reporting. Prior to this, Kristin held various positions at PwC from September 2007 to July 2019, progressing from Associate to Director. Kristin began the accounting career as an Assurance Intern at PwC in 2006. Academically, Kristin holds a Bachelor of Science in Business Administration with a focus on Accounting from Bryant University and a Masters of Science in Accountancy from Boston College.
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).